NKCx Histopathological outcome* within 12 months after cervix cytology in 2018
231 Jönköping

  Benign CIN1 CIN2 CIN3 AIS Cancer Other PAD missing Total
Cytology Count Pct Count Pct Count Pct Count Pct Antal Andel Count Pct Count Pct Count Pct Count Pct
Benign sample 61 0.7% 4 0.0% . . 2 0.0% . . 1 0.0% 3 0.0% 8927 99.2% 8998 100.0%
ASCUS 180 28.2% 91 14.2% . . 64 10.0% . . 1 0.2% 32 5.0% 271 42.4% 639 100.0%
CIN1 58 22.9% 73 28.9% . . 43 17.0% . . 1 0.4% 11 4.3% 67 26.5% 253 100.0%
Atypical glandular cells/AGC 2 16.7% 2 16.7% . . 2 16.7% 2 16.7% 2 16.7% . . 2 16.7% 12 100.0%
Unclear atypia 3 27.3% 2 18.2% . . 4 36.4% . . 1 9.1% 1 9.1% . . 11 100.0%
ASC-H 10 20.4% 5 10.2% . . 32 65.3% . . 1 2.0% 1 2.0% . . 49 100.0%
CIN3 6 5.9% 11 10.9% . . 76 75.2% 1 1.0% 5 5.0% 2 2.0% . . 101 100.0%
Adenocarcinoma . . . . . . 1 100.0% . . . . . . . . 1 100.0%
Malignant tumor with unclear origin . . . . . . 1 100.0% . . . . . . . . 1 100.0%
Squamous cell cancer . . . . . . 1 100.0% . . . . . . . . 1 100.0%
Total 320 3.2% 188 1.9% . . 226 2.2% 3 0.0% 12 0.1% 50 0.5% 9267 92.1% 10066 100.0%

NOTE: Histopathological outcome from T83x taken into account.
This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad.

* Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead.
The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'.
Process Registry's Class 1 (benign), 2d (CIN1) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories.
 

Snomed codes in the category Cancer:
M80703, M81401, M81403, M83803